News tagged with tyrosine kinase inhibitor

Related topics:

Economic analysis: Erlotinib marginally cost-effective

Weighing both magnitude of survival benefit and expense, researchers found that the drug erlotinib, which was found to improve overall survival by 2 months in patients with advanced non-small cell lung cancer, is marginally ...

dateFeb 16, 2010 in Cancer
shares0 comments 0